Bright Peak Therapeutics Appoints Leena Gandhi, M.D., Ph.D., to its Board of Directors
February 28, 2022 16:00 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO and BASEL, Switzerland, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and...
Bright Peak Therapeutics beruft Dr. Leena Gandhi, MD, in seinen Vorstand
February 28, 2022 16:00 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO, Kalifornien (USA) und BASEL (Schweiz), Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, ein Biotechnologieunternehmen, das Zytokin-Immuntherapien der nächsten Generation zur...
Bright Peak Therapeutics ernennt Jacob Chacko, M.D., zum Vorsitzenden des Verwaltungsrats
November 29, 2021 18:06 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO und BASEL, Schweiz, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, ein Biotechnologieunternehmen, das Zytokin-Immuntherapien der nächsten Generation zur Behandlung von Krebs-...
Bright Peak Therapeutics Appoints Jacob Chacko, M.D., as Chair of its Board of Directors
November 29, 2021 16:00 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO and BASEL, Switzerland, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and...
Bright Peak Therapeutics lizenziert Rechte an Anti-PD-1-Antikörper LZM009 von Livzon zur Entwicklung neuartiger, auf PD-1 abzielender Immunzytokine
November 16, 2021 12:00 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO und BASEL, Schweiz, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, Inc., ein Biotechnologieunternehmen, das Zytokin-Immuntherapien der nächsten Generation entwickelt, hat...
Bright Peak Therapeutics Licenses Rights to Livzon’s Anti-PD-1 Antibody LZM009 to Develop Novel PD-1 Targeted Immunocytokines
November 16, 2021 12:00 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO and BASEL, Switzerland, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, Inc., a biotechnology company developing next-generation cytokine immunotherapies, today announced that...
Bright Peak Therapeutics gibt Serie-B-Finanzierungsrunde in Höhe von 107 Millionen US-Dollar und Erweiterung des Vorstands bekannt
June 10, 2021 15:43 ET
|
Bright Peak Therapeutics, Inc.
--Mit den Erlösen wird die Pipeline des Unternehmens an Zytokin-Immuntherapien der nächsten Generation vorangetrieben----Laura Shawver, Christine Siu ergänzen Vorstand als unabhängige...
Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors
June 10, 2021 08:00 ET
|
Bright Peak Therapeutics, Inc.
--Proceeds to advance company’s pipeline of next-generation cytokine immunotherapies----Laura Shawver, Christine Siu join as independent directors-- BASEL, Switzerland and SAN DIEGO, Calif., June ...
Bright Peak Therapeutics Inc. and Ajinomoto Co., Inc. Enter into a Research Collaboration and License Agreement to Create Novel Immunocytokines
March 25, 2021 20:00 ET
|
Bright Peak Therapeutics, Inc.
SAN DIEGO and TOKYO, March 25, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics Inc., a biotechnology company developing next generation immunotherapies for cancer and autoimmune disease, and...